Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Newborn Testing for Immune Disorders Could Save Lives


A simple, inexpensive blood test performed at birth to screen for immune disorders could dramatically increase the chance of survival for babies born with such potentially fatal disorders as severe combined immunodeficiency disease (SCID).

Rebecca H. Buckley, M.D.
Credit: Duke University Medical Center

Physicians at Duke University Medical Center have performed stem cell transplants in 136 infants with SCID in the past 22 years. The survival rate for 38 infants receiving transplants in the first 3.5 months of life is 97 percent, but the rate drops to 69 percent for infants who were transplanted after that age, Rebecca Buckley, M.D., reports in the April 23, 2004, Annual Review of Immunology.

The main cause for the drop in survival rate is serious infections SCID babies develop in the first few months of life. Infants with SCID have little or no immune system. Without treatment, they die of infection before their first or second birthdays. But for infants without a known family history of SCID, the average age of referral for immune testing is approximately 6 months, Buckley said. "The tragedy is that most patients are critically ill by then,’’ she said.

Buckley believes that all newborns should be screened for immune deficiency disorders at birth. "SCID is a pediatric emergency. There is no screening for any primary immunodeficiency disease at birth or during childhood and adulthood in any country. Thus, most patients are not diagnosed until they develop a serious infection, which certainly adversely affects the outcome of therapy," said Buckley, a professor in Duke’s division of pediatric allergy and immunology.

Early treatment also reduces costs -- a transplant in the first three months of life can cost less than $50,000, but the cost of care skyrockets up to millions of dollars for seriously ill patients, with less guarantee of success. And SCID patients who received stem cell transplants from related donors within the first 28 days of life developed a more robust immune system, with higher levels of T cell reconstitution and output from the thymus gland. T cells are white blood cells that are essential for normal function of the immune system, Buckley reports.

Nearly all SCID cases can be diagnosed at birth by counting the number of lymphocytes, a type of white blood cell, present in umbilical cord blood, Buckley said. Infants with SCID have a profound deficiency of lymphocytes, due to the deficiency of T cells that help fight infections. Children with other immune disorders could also be identified through this test, which costs an average of $50 at a commercial laboratory. Researchers at the National Humane Genome Research Institute are developing a test for immunodeficiency disorders that could be performed on the small blood sample now taken from newborns to screen for certain metabolic disorders.

Nine forms of SCID have been identified in the past 10 years, caused by mutations of single genes. However, Buckley has treated 30 patients without mutations in the known SCID genes, making it likely other causes are yet to be discovered. The most common form of SCID is X-linked recessive, a mutation inherited on the X chromosome. Because X-linked recessive genes are expressed in girls only if a child receives two copies of the gene -- one from each parent -- the disease is more common in boys, who only need one copy for an X-linked recessive gene to be expressed. SCID-X1 accounts for 46 percent of U.S. cases.

The incidence of SCID has been projected to range from one in every 100,000 to 500,000 births -- more frequent than disorders such as Huntington’s disease. "However, no one truly knows how common this disease is. I suspect that it is much more common than thought because a lot of SCID patients probably die before their disease is recognized," Buckley said.

Buckley and her colleagues at Duke University Medical Center treat SCID patients via stem cell transplants derived from donor bone marrow, typically from a parent or matched sibling. Transplant recipients do not need pretransplant chemotherapy or prophylactic treatment for graft-versus-host disease. Infants with SCID have a complete absence of T cell function, so they cannot reject the transplants. The bone marrow is processed to remove T cells, preventing the donor T cells from attacking the recipient, known as graft-versus-host disease. Mature, donor-derived, T cells typically appear in SCID patients within 90 to 120 days after transplant. The success of treatment varies among different forms of SCID.

Clinicians are striving to improve the success of transplant therapy and create more robust immune systems by giving higher numbers of stem cells in preparations nearly devoid of T cells, Buckley added. "If the imperfect results seen with stem cell therapy in the past were due to an insufficient number of stem cells, this approach should result in better immune reconstitution. The only remaining obstacle would then be to ensure diagnosis is made early before untreatable infections develop," she said.

Of the 136 SCID patients treated at Duke, 105 (77 percent) are alive. None show any evidence of susceptibility to opportunistic infections and most are in good general health. The oldest is 22 years of age. All 15 recipients of marrow from perfectly matched donors and 89 of the 121 recipients of T cell-depleted marrow from related donors are among the survivors.

Of the 38 infants transplanted during the first 3.5 months of life, 37 (97 percent) survive, compared to 68 survivors among the 98 transplanted after that age (69 percent success). Twenty-four of the 31 deaths occurred from viral infections. Graft-versus-host-disease (GVHD) occurred in 40 of the 121 patients given T cell-depleted parental bone marrow, but most of the GVHD was mild and required no treatment; there were no deaths from GVHD. In 35 of 40 GVHD cases, the complication occurred when there was persistence of transplacentally transferred maternal T cells.

Becky Oskin | dukemed news
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>